

**am**  
ASSOCIAZIONE ITALIANA  
**MIOLOGIA**  
ITALIAN ASSOCIATION OF MYOLOGY

**XXIV NATIONAL CONGRESS  
OF ITALIAN ASSOCIATION  
OF MYOLOGY**


**ROME**

**5 - 8 June 2024**

**PROGRAM**

# Il XXIV National Congress of Italian Association of Myology

si svolge con i patrocini di:



## INDICE

---

pag. 01 | Consiglio Direttivo  
03 | Faculty

## PROGRAMMA

pag. 05 | Wednesday, 5 June 2024  
07 | Thursday, 6 June 2024  
12 | Friday, 7 June 2024  
16 | Saturday, 8 June 2024





# CONSIGLIO DIRETTIVO





### **Consiglio Direttivo**

Prof. Giacomo Pietro Comi - Presidente  
Prof. Carlo Minetti - Past President  
Prof.ssa Olimpia Musumeci - Segretario  
Prof. Luca Bello - Tesoriere

### **Membri**

Dott.ssa Adele D'Amico  
Prof. Rocco Liguori  
Dott. Lorenzo Maggi  
Prof. Michelangelo Mancuso  
Prof. Vincenzo Nigro  
Dott.ssa Federica Ricci

[www.miologia.org](http://www.miologia.org)





# FACULTY



## FACULTY

---

Emilio Albamonte, Milano  
Corrado Angelini, Padova  
Giovanni Antonini, Roma  
Rita Barresi, Venezia  
Luca Bello, Padova  
Alfredo Berardelli, Roma  
Angela Lucia Berardinelli, Pavia  
Enrico Bertini, Roma  
Silvia Bonanno, Milano  
Jim Bonham, Sheffield  
Paul Boon, Eindhoven  
Annalisa Botta, Roma  
Claudio Bruno, Genova  
Giorgia Camera, Bergamo  
Stefano Canestrari, Bologna  
Michela Catteruccia, Roma  
Giacomo Pietro Comi, Milano  
Stefania Corti, Milano  
Adele D'Amico, Roma  
Antonio Di Muzio, Chieti  
Vincenzo Di Stefano, Palermo  
Daria Diodato, Roma  
Carmen Erra, Napoli  
Antonio Farina, Lione  
Alessandra Ferlini, Ferrara  
Massimiliano Filosto, Brescia  
Fabiana Fattori, Roma  
Laura Fionda, Roma  
Delio Gagliardi, Bari  
Matteo Garibaldi, Roma  
Francesco Habetswallner, Napoli  
Raffaele Iorio, Roma  
Maurizio Inghilleri, Roma  
Costanza Lamperti, Milano  
Rocco Liguori, Bologna  
Matteo Lucchini, Roma  
Lorenzo Maggi, Milano  
Francesca Magri, Milano  
Michelangelo Mancuso, Pisa  
Roberto Massa, Roma  
Riccardo Masson, Milano  
Giovanni Meola, Milano  
Eugenio Maria Mercuri, Roma  
Sonia Messina, Messina

Margherita Milone, Rochester  
Carlo Minetti, Genova  
Massimiliano Mirabella, Roma  
Maurizio Gualtieri Moggio, Milano  
Tiziana Mongini, Torino  
Federica Montagnese, Messina  
Olimpia Musumeci, Messina  
Vincenzo Nigro, Napoli  
Marika Pane, Roma  
Giancarlo Parenti, Napoli  
Elena Pennisi, Roma  
Antonio Petrucci, Roma  
Daniela Piga, Milano  
Luisa Politano, Napoli  
Stefano Previtali, Milano  
Guido Primiano, Roma  
Susana Quijano Roy, Garches  
Giulia Ricci, Pisa  
Enzo Ricci, Roma  
Federica Ricci, Torino  
Andrea Romigi, Pozzilli  
Dario Ronchi, Milano  
Carmelo Rodolico, Messina  
Marcello Romano, Palermo  
Vincenzo Russo, Napoli  
Francesco Saccà, Napoli  
Cristina Sancricca, Roma  
Valeria Sansone, Milano  
Marco Savarese, Helsinki  
Serenella Servidei, Roma  
Gabriele Siciliano, Pisa  
Gabriella Silvestri, Roma  
Jan Smeitink, Nijmegen  
Antonella Spinazzola, Londra  
Volker Straub, Newcastle upon Tyne  
Giorgio Tasca, Newcastle upon Tyne  
Paola Tonin, Verona  
Yvan Torrente, Milano  
Antonio Toscano, Messina  
Federica Trucco, Milano  
Antonio Varone, Napoli  
Daniele Velardo, Milano  
Massimo Domenico Zeviani, Padova  
Ester Zito, Milano



ALF·COSTERTIVM·FECIT

# PROGRAMMA





Wednesday, 5 June 2024

**GIOVE HALL**



**14:30 - 15:00 | GREETINGS AND INTRODUCTION**

*Alfredo Berardelli (Roma) - Past President SIN*  
*Serenella Servidei (Roma)*  
*Giacomo Pietro Comi (Milano)*

**15:00 - 15:30 | MAIN LECTURE I**

Chairperson: *Giacomo Pietro Comi (Milano)*

The increasing complexity in the diagnoses and treatment of genetic muscle diseases.  
*Volker Straub (Newcastle upon Tyne) - President of WMS*

**15:30 - 17:00 | WORKSHOP**

**Myotonic Dystrophy - Part I**

Chairpersons: *Giovanni Meola (Milano), Gabriele Siciliano (Pisa)*

**15:00 | Unravelling the complexity of the DM repeat expansions:  
implications for the genotype-phenotype correlations**  
*Annalisa Botta (Roma)*

**15:30 | Identifying biomarkers of organ involvement in DM1**  
*Gabriella Silvestri (Roma)*

**16:00 | Towards an Italian consensus on the management of cardiological alterations in the DM**  
*Vincenzo Russo (Napoli)*

**16:30 | Hypersomnia and sleep-related breathing disorders in myotonic dystrophy type 1  
and type 2: diagnosis and treatment**  
*Andrea Romigi (Pozzilli)*

**17:00 - 17:30 | Coffee Break**

**17:30 - 18:00 | WORKSHOP**

**Myotonic Dystrophy- Part II**

Chairpersons: *Fabiana Fattori (Roma), Carmelo Rodolico (Messina)*

**17:30 | Outcome and intervention in Paediatric DM1**  
*Valeria Sansone (Milano)*

**17:40 | Treatment development pipeline in the DM1**  
*Roberto Massa (Roma)*

**17:50 | Myotonic dystrophy type 2: still underdiagnosed? How to improve disease awareness**  
*Federica Montagnese (Messina)*

18:00 - 18:30 | **MAIN LECTURE II**

Chairperson: *Vincenzo Nigro (Napoli)*

Preimplantation genetic testing and prenatal diagnosis: fundamental rights and bioethics  
*Stefano Canestrari (Bologna)*

---

18:30 - 19:00 | **LECTURE - SPONSORIZED BY NOVARTIS** **NO CME**

**The latest evidence in the treatment paradigm of Spinal Muscular Atrophy.**

Chairperson: *Marika Pane (Roma)*

From Clinical Trials to Clinical Practice: anticipating the future and exploring novel aspects of the disease.

*Adele D'Amico (Roma), Antonio Varone (Napoli)*

19.00 - 21.00 | **GET TOGETHER COCKTAIL**

Thursday, 6 June 2024

GIOVE HALL



08:30 - 09:15 | **SYMPOSIUM - SPONSORIZED BY DYNE** **NO CME**  
**Advancements in Neuromuscular Disorder Therapeutics:  
Lessons Learned in DMD and Emerging Perspectives in DM1 Therapeutic Development**  
Chairperson: *Eugenio Mercuri (Roma)*

08:30 | Lessons Learned from DMD and Update on the DELIVER Ongoing Phase 1/2 Trial  
*Marika Pane (Roma)*

08:55 | Insights from DM1 Natural History and an Update on the ACHIEVE Ongoing  
Phase 1/2 Clinical Trial  
*Valeria Sansone (Milano)*

09:15 - 09:45 | **MAIN LECTURE III**  
Chairperson: *Antonio Toscano (Messina)*

Promoting brain health through novel anti-seizure treatments  
*Paul Boon (Eindhoven) - President European Academy of Neurology*

09:45 -10:15 | **MAIN LECTURE IV**  
Chairperson: *Antonio Toscano (Messina)*

Epilepsy in Mitochondrial Disorders  
*Michelangelo Mancuso (Pisa)*

10:15 - 10:30 | Coffee Break

10:30 - 11:30 | **MUSCLE TriviAIM- Fase eliminatória**  
Chairperson: *Serenella Servidei (Rome), Olimpia Musumeci (Messina)*



11:30 - 13:00 | **PLENARY WORKSHOP 1**  
**Current and future perspectives of genomic NBS: are we ready to deal with it?**  
Chairpersons: *Carlo Minetti (Genova), Elena Pegoraro (Padova)*

11:30 | Where are we now  
*Jim Bonham (Sheffield)*

11:50 | Genome NBS: the Screen4Care EU project  
*Alessandra Ferlini (Ferrara)*

12:20 | Barriers and opportunities  
*Vincenzo Nigro (Napoli)*

12:40 | The political side: LEA vs real life  
*TBD*



## GIUNONE HALL 1



10:15 - 14:00 | **POSTER SESSION I**

**NO CME**

## GIOVE HALL



14:00 - 15:00 | **SYMPOSIUM - SPONSORIZED BY BIOGEN**

**NO CME**

### **Biomarkers and the Development of an Evidence Based Medicine Approach in Spinal Muscular Atrophy**

14:00 | Welcome and introduction  
*Valeria Sansone (Milano)*

14:10 | Generating evidence and interpreting data from heterogeneous population  
*Eugenio Maria Mercuri (Roma)*

14:30 | Biomarkers to stratify for disease progression and to monitor treatment efficacy  
*Stefania Corti (Milano)*

14:50 | Discussion

15:00 - 16:00 | **SYMPOSIUM - SPONSORIZED BY ROCHE**

**NO CME**

### **THE NEW GENERATION OF SMA PATIENTS**

Chairperson: *Marika Pane (Roma)*

15:00 | New disease trajectories, new expectations  
*Marika Pane (Roma)*

15:15 | Going beyond motor functions: the bulbar assessment  
*Riccardo Masson (Milano)*

15:30 | Going beyond motor functions: the respiratory assessment  
*Federica Trucco (Milano)*

15:45 | Discussion

16:00 - 16:30 | Coffee Break



**16:30 - 17:30 | ORAL COMMUNICATION | MYASTHENIA GRAVIS - TRANSVERSAL**Chairpersons: *Giovanni Antonini (Roma), Rocco Liguori (Bologna)*

- 16:30** | Ocular myasthenia vs generalized myasthenia gravis with ocular onset: clinical outcomes from a single-centre retrospective study  
*Alessia Pugliese (Messina)*
- 16:42** | Preferential binding to adult or fetal acetylcholine receptor isoform as a promising predictive biomarker in myasthenia gravis  
*Francesca Beretta (Firenze)*
- 16:54** | A multicentre, prospective study comparing autoantibody diagnostic assays in myasthenia gravis  
*Laura Degiglio (Roma)*
- 17:06** | Effectiveness of thymectomy in juvenile myasthenia gravis: preliminary results of a 15-year follow up study  
*Michelangelo Maestri Tassoni (Pisa)*
- 17:18** | Clinical outcome measures in a prospective cohort of myasthenia gravis patients  
*Massimiliano Ugo Verza (Firenze)*

**GIUNONE HALL 1****16:30 - 17:30 | ORAL COMMUNICATION | MYOTONIC DYSTROPHIES**Chairpersons: *Costanza Lamperti (Milano), Mauro Monforte (Roma)*

- 16:30** | Cardiac risk and myocardial fibrosis assessment with Cardiac Magnetic Resonance in patients with Myotonic Dystrophy  
*Elena Abati (Milano)*
- 16:42** | Muscle MRI as a biomarker of disease activity and progression in Myotonic Dystrophy type 1: a longitudinal study  
*Laura Tufano (Roma)*
- 16:54** | Prevalence of AF atrial fibrillation in patients with MD1 Myotonic Dystrophy type 1: a retrospective 16-years follow up  
*Antonio Petrucci (Roma)*
- 17:06** | THE METMYD STUDY: baseline data and early results on efficacy and safety of metformin in myotonic dystrophy type 1  
*Erica Frezza (Roma)*
- 17:18** | Proof of concept for drug repurposing of fenamates in myotonia congenita  
*Ilaria Saltarella (Bari)*

## GIUNONE HALL 2



### 16:30 - 17:30 | ORAL COMMUNICATION | METABOLIC MYOPATHIES

Chairpersons: *Massimiliano Filosto (Brescia), Elena Pennisi (Roma)*

16:30 | Transition in Glycogen Storage Disease type 2 (GSD2): state of art in Italian Centers

*Liliana Vercelli (Torino)*

16:42 | Quantitative muscle MRI in individual thigh muscles in early Pompe disease

*Michele Giovanni Croce (Pavia)*

16:54 | Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease

*Antonio Toscano (Messina)*

17:06 | Clinical and laboratory follow-up in a cohort of lipid storage myopathies: a single center experience

*Mattia Porcino (Messina)*

17:18 | A comprehensive evaluation of mobile health technology revealed the ability to identify subtle motor impairment in patients with mild and asymptomatic Pompe disease: one-year follow-up

*Lucia Ferullo (Brescia)*

## GIOVE HALL



### 17:30 - 18:30 | ORAL COMMUNICATION | MYASTHENIA GRAVIS - THERAPIES

Chairpersons: *Maurizio Inghilleri (Roma), Francesco Saccà (Napoli)*

17:30 | Achievement of Minimal Symptom Expression in Acetylcholine-Receptor Antibody-Positive Participants with Generalized Myasthenia Gravis and Effect on Disease-Specific Measures in ADAPT/ADAPT+ Studies

*Rita Frangiamore (Milano)*

17:42 | Efgartigimod in non-AChR generalized myasthenia gravis

*Carlo Antozzi (Roma)*

17:54 | A Real-life experience with Eculizumab and Efgartigimod in generalized Myasthenia Gravis patients

*Laura Fionda (Roma)*

18:06 | Rituximab in refractory myasthenia gravis: 5 year single center follow up

*Dario Ricciardi (Napoli)*

18:18 | Eculizumab in refractory generalized Myasthenia Gravis: a single center 1 year experience

*Carmen Erra (Napoli)*



## GIUNONE HALL 1

### 17:30 - 18:30 | ORAL COMMUNICATION | MUSCULAR DYSTROPHIES

Chairpersons: *Federica Trucco (Milano), Angela Berardinelli (Pavia)*

17:30 | SYNE-1 and SYNE-2 mutations: expanding the genotype and phenotype spectrum of nesprinopathies

*Marta Cheli (Verona)*

17:42 | Emerin is involved in microtubule-organizing center (MTOC) relocalization to the nuclear surface: altered dynamics in type 1 Emery-Dreifuss Muscular Dystrophy

*Elisabetta Mattioli (Bologna)*

17:54 | In search of biomarkers for Emery-Dreifuss Muscular Dystrophy

*Giovanna Lattanzi (Bologna)*

18:06 | Novel biomarkers for limb-girdle muscular dystrophy associated to CAPN3 mutation

*Diego Lopercolo (Siena)*

18:18 | Unraveling of the innate immune system and the complement activation in FSHD cellular muscle models towards the identification of disease biomarkers

*Elisabetta Ferraro (Pisa)*

## GIUNONE HALL 2

### 17:30 - 18:30 | ORAL COMMUNICATION | LATEST DEVELOPMENT IN MYOPATHIES

Chairpersons: *Marcello Romano (Palermo), Giulia Ricci (Pisa)*

17:30 | Muscle MRI findings in Italian patients with myofibrillar and distal myopathies: an exploratory analysis from ITA-MeD

*Sara Bortolani (Roma)*

17:45 | Myositis with mitochondrial pathology: a multicentric case series

*Antonio Lauletta (Roma)*

18:00 | Pathogenic TNNI1 variants cause muscle disease manifesting as either a hypo- (recessively inherited) or a hyper- (dominantly inherited) contractile phenotype

*Francesca Magri (Milano)*

18:15 | Treatment of active idiopathic inflammatory myopathies by inhibiting FcRn:

Pre-registration report of ALKIVIA, a phase 2/3 trial with efgartigimod

*Massimiliano Mirabella (Roma)*

## GIOVE HALL

### 18:30 - 19:00 | MAIN LECTURE V

Chairperson: *Sonia Messina (Messina)*

State of the art of therapy for Duchenne Muscular Dystrophy

*Luca Bello (Padova)*

Friday, 7 June 2024

## GIOVE HALL

19:00 - 19:30 | **LECTURE - SPONSORIZED BY ITALFARMACO** **NO CME**

The Italian contribution to scientific innovation in Duchenne musculare dystrophy research  
*Eugenio Mercuri (Roma)*

08:30 - 10:00 | **PLENARY WORKSHOP 2**

**Sporadic Inclusion Body Myositis: Updates on diagnostic clues and therapeutic perspective**

Chairpersons: *Maurizio Moggio (Milano), Antonio Petrucci (Roma)*

08:30 | Latest acquisitions on s-IBM physiopathology and potential impact for newer therapeutic approaches  
*Lorenzo Maggi (Milano)*

09:00 | The value of the laboratoristic and imaging findings in s-IBM diagnosis and research: from anti-CN1A antibodies to muscle MRI  
*Giorgio Tasca (Newcastle upon Tyne)*

09:30 | Looking for reliable clinical and instrumental outcome measures in s-IBM  
*Matteo Lucchini (Roma)*

## GIUNONE HALL 2

08:30 - 10:00 | **PARALLEL WORKSHOP 3**

**Diagnostic tools for congenital myopathies**

Chairpersons: *Enrico Bertini (Roma), Claudio Bruno (Genova)*

08:30 | Clinical framing  
*Margherita Milone (Rochester)*

08:50 | Genomic approach  
*Marco Savarese (Helsinki)*

09:10 | MYO-MRI for congenital myopathies  
*Susana Quijano Roy (Garches)*

09:20 | Biomarkers  
*Ester Zito (Milano)*

## GIOVE HALL

10:00 - 10:30 | **MAIN LECTURE VI**

Chairperson: *Tiziana Mongni (Torino)*

Optimizing therapeutic options in the management of Pompe disease  
*Olimpia Musumeci (Messina)*

## GIOVE HALL

10:30 - 11:00 | Coffee Break

11:00 - 12.30 | **PLENARY WORKSHOP 4**

**Mitochondrial diseases: from the emergency department to the new therapies. Avenues and pitfalls**

Chairpersons: *Antonella Spinazzola (Londra), Dario Ronchi (Milano)*

11:00 | Management of acute metabolic crisis  
*Serenella Servidei (Roma)*

11:20 | Update on Leigh Syndrome  
*Enrico Bertini (Roma)*

11:40 | Therapeutic developments in Friedreich Ataxia  
*Yvan Torrente (Milano)*

12:10 | Focusing on regulatory aspects in neuromuscular disease  
*Jan Smeitink (Nijmegen)*

## GIUNONE HALL 1

10:30 - 13:30 | **POSTER SESSION PART II** **NO CME**

## GIOVE HALL

13:30 - 14.30 | **SYMPOSIUM - SPONSORIZED BY ARGENX** **NO CME**  
**Exploring the role of efgartigimod from clinical trials to real practice in gMG**

Chairpersons: *Lorenzo Maggi (Milano), Raffaele Iorio (Roma)*

13:30 | Welcoming

13:35 | MG: an IgG mediated disease  
*Raffaele Iorio (Roma)*

13:45 | Long-term efficacy and safety of efgartigimod  
*Vincenzo Di Stefano (Palermo)*

14:00 | Moving beyond clinical trials for patient identification  
*Lorenzo Maggi (Milano)*

14:05 | Real Life experience with efgartigimod  
*Giorgia Camera (Bergamo)*

14:20 Discussion



14:30 - 15:30 | **SYMPOSIUM - SPONSORIZED BY ALEXION** **NO CME**  
**ECULIZUMAB: A YEAR OF VALIDATION FROM TRIAL DATA TO REAL WORLD EXPERIENCE**

Chairpersons: *Francesco Habetswallner (Napoli), Roberto Massa (Roma)*

14:30 | Disease Fluctuations Control  
*Carmen Erra (Napoli)*

14:45 | Early Responders vs Late Responders  
*Silvia Bonanno (Milano)*

15:00 | Reduction of Concomitant Therapies  
*Laura Fionda (Roma)*

15:15 | Discussion

15:30 - 16:00 | Coffee Break

16:00 - 17.30 | **PLENARY WORKSHOP 5**

**Idiopathic Inflammatory Myopathies:**

**Diagnostic Challenges, New Entities, And Future Therapeutical Approaches**

Chairpersons: *Matteo Garibaldi (Roma), Antonio Di Muzio (Chieti)*

16:00 | New molecular targets for IIMs: from immunopathology to clinical trials  
*Massimiliano Mirabella (Roma)*

16:30 | Immune checkpoint inhibitor-associated myositis:  
risk factor, disease courses and therapeutic approach  
*Antonello Farina (Lione)*

17:00 | Muscle MRI and imaging biomarkers: role on diagnosis and follow-up of IIM  
*Stefano Previtali (Milano)*

17:30 - 18:30 | **SYMPOSIUM - SPONSORIZED BY AMICUS**

**NO CME**

**How to improve the management of Pompe Disease**

Charipersons: *Tiziana Mongini (Torino), Antonio Toscano (Messina)*

17:30 | Rationale for the use of small molecules in LSD

*Giancarlo Parenti (Napoli)*

17:45 | Management and follow-up of the patient with Pompe disease

*Cristina Sancricca (Roma)*

18:00 | Can cell damage be limited?

*Antonio Toscano (Messina)*

18:15 Discussion

18:30 - 19:30 | **GENERAL ASSEMBLY**



**Saturday, 8 June 2024**

## **GIOVE HALL**



### **08:30 - 09:30 | ORAL COMMUNICATION | SMA**

Chairpersons: *Emilio Albamonte (Milano), Delio Gagliardi (Bari)*

**08:30 | RAINBOWFISH: Primary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA)**  
*Enrico Bertini (Roma)*

**08:42 | Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome?**  
*Costanza Cutrona (Roma)*

**08:54 | Fragility fractures prevalence and bone health in a large cohort of untreated SMA patients**  
*Chiara Panicucci (Genova)*

**09:06 | Single-center long-term follow-up of 18 patients with Spinal Muscular Atrophy (SMA) treated with risdiplam**  
*Simona Damioli (Roma)*

**09:18 | MFM-32 motor scale in adult SMA patients after risdiplam treatment: a single centre experience.**  
*Maria Sframeli (Messina)*

## **GIUNONE HALL 1**



### **08:30 - 09:30 | ORAL COMMUNICATION | FSHD**

Chairpersons: *Enzo Ricci (Roma), Corrado Angelini (Padova)*

**08:30 | Enhancing FSHD Diagnosis: a one-year follow-up study on the Efficacy of a Combined Methylation Assay and Machine Learning Pipeline**  
*Domenica Megalizzi (Roma)*

**08:42 | Evaluation of non-invasive biological sources for assessing methylation levels of FSHD-associated locus**  
*Claudia Strafella (Roma)*

**08:54 | Clinical variability and molecular complexity of FSHD: relevance of deep phenotyping and comprehensive genetics in characterizing atypical clinical cases**  
*Francesca Torri (Pisa)*

**09:06 | Diaphragmatic Ultrasonography in the respiratory assessment of Facioscapulohumeral Muscular Dystrophy (FSHD): a promising approach for management and longitudinal follow-up**  
*Eleonora Torchia (Roma)*



09:18 | Molecular imaging of muscle involvement in facioscapulohumeral muscular dystrophy using multispectral optoacoustic tomography  
*Mauro Monforte (Roma)*

## GIUNONE HALL 2



### 08:30 - 09:30 | ORAL COMMUNICATION | GENOMIC

Chairpersons: *Paola Tonin (Verona), Michela Catteruccia (Roma)*

08:30 | Next-generation sequencing for the diagnosis of primary muscle disorder: the experience of the Dino Ferrari Center in Milan  
*Dario Ronchi (Milano)*

08:42 | Recurrent TTN missense variants in biallelic titinopathies: a focus on Proline changes  
*Maria Francesca Di Feo (Genova)*

08:54 | Beyond exome-targeted sequencing approaches to increase the diagnostic rate of unsolved neuromuscular disease patients  
*Pasquale Di Letto (Napoli)*

09:06 | Computational Models for new Patients Stratification Strategies of Neuromuscular Disorders: a new strategy to tackle hereditary neuromuscular disorders  
*Rossella Tupler (Modena)*

09:18 | Beyond the exome: a very complex diagnosis of myofibrillar myopathy solved by genomic long read sequencing  
*Annalaura Torella (Napoli)*

## GIOVE HALL



### 09:30 - 10:30 | ORAL COMMUNICATION | MITOCHONDRIAL

Chairpersons: *Daria Diodato (Roma), Massimo Zeviani (Padova)*

09:30 | Developing AAV gene therapy for mitochondrial myopathies  
*Carlo Viscomi (Padova)*

09:42 | Urolithin A as a potential treatment for mitochondrial myopathies  
*Valeria Balmaceda (Padova)*

09:54 | A Pilot Phase 2 Randomized Trial to Evaluate the Safety and Potential Efficacy of Etravirine in Friedreich Ataxia Patients  
*Andrea Martinuzzi (Conegliano)*

10:06 | Serum neurofilament light chain in mitochondrial diseases: exploring a new promising biomarker.  
*Guido Primiano (Roma)*

10:18 | Role of muscle biopsy in mitochondrial myopathy: genotype-phenotype correlation  
*Dario Zoppi (Napoli)*



## GIUNONE HALL 1



### 09:30 - 10:30 | **ORAL COMMUNICATION | DUCHENNE MUSCULAR DYSTROPHY**

Chairpersons: *Luisa Politano (Napoli), Stefano Previtali (Milano)*

09:30 | Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy (EMBARC): Pivotal Phase 3 Primary results  
*Eugenio Maria Mercuri (Roma)*

09:42 | Extensive next-generation sequencing approaches for the identification of rare genomic structural variants involving the DMD gene  
*Rita Selvatici (Ferrara)*

09:54 | Gut microbiota signature in Duchenne Muscular Dystrophy  
*Chiara Panicucci (Genova)*

10:06 | The hidden face of Duchenne (Neuro)Muscular Dystrophy: social cognition impairment as a feature of the neuropsychological phenotype of DMD  
*Stefano Parravicini (Pavia)*

10:18 | Nonsense mutations in Becker muscular dystrophy: DMD gene position and disease severity  
*Domenico Gorgoglione (Padova)*

## GIUNONE HALL 2



### 09:30 - 10:30 | **ORAL COMMUNICATION | EXPERIMENTAL MODELS**

Chairpersons: *Daniela Piga (Milano), Rita Barresi (Venezia)*

09:30 | Creation of a Zebrafish model of LGMDD2 and role of TNPO3 in the pathogenetic mechanism  
*Roberta Costa (Roma)*

09:42 | Yeast NDI1 rescues muscular NDUFS3<sup>-/-</sup> mouse model: a new prospect of flexible gene therapy for complex-I deficiencies  
*Daniele Sala (Milano)*

09:54 | Engineering 3D Models to Investigate LGMDD2 Transportin 3 Related: Insights into Myogenic Processes and Contractile Dysfunction  
*Serafina Pacilio (Bologna)*

10:06 | Modeling Myotonic Dystrophy type 2 in human cerebral organoids  
*Paola Spitalieri (Roma)*

10:18 | Patient-derived organoids as a new in vitro paradigm to study Myotonic Dystrophy type 1  
*Lorenzo Fontanelli (Pisa)*



10:30 - 11:30 | **MUSCLE TriviAIM - THE FINAL**  
Chairpersons: *Serenella Servidei (Rome), Giacomo Pietro Comi (Milan)*



11:30 - 13:30 | **ROUND TABLE MEETING with PATIENT'S ASSOCIATIONS**  
Chairperson: *Giacomo Pietro Comi (Milano), Federica Ricci (Torino)*

Intervengono:

<i>Francesco Ieva</i>	<b>Altro Domani</b>	
<i>Elisabetta Conti</i>	<b>AIG</b>	
<i>Anita Pallara</i>	<b>Famiglie SMA</b>	
<i>Beatrice Vola</i>	<b>GFB Gruppo Familiari Beta-sarcoglicanopatie</b>	
<i>Paula Morandi</i>	<b>Mitocon</b>	
<i>TBD</i>	<b>Parent Project</b>	
<i>Danila Baldessarri</i>	<b>Telethon</b>	
<i>Stefania Pedroni</i>	<b>UILDM</b>	

---

13:30 | **AWARDS AND CONCLUSIONS**

---



# INFORMAZIONI GENERALI

---

## SEDE CONGRESSUALE

### A. ROMA LIFESTYLE HOTEL

Via Giorgio Zoega, 59  
00164 Roma

## SEGRETERIA ORGANIZZATIVA



First Class - Meetings and Conferences

Sede Milano

Via Vittoria Colonna 40 - 20149 Milano

Ph. +39 02 30066329

aim2024@fclassevents.com

www.fclassevents.com

La Segreteria Organizzativa sarà a disposizione dei partecipanti presso la Sede Congressuale durante i seguenti orari:

- Mercoledì 5 giugno dalle 09.00 fino al termine dei lavori
- Giovedì 6 giugno dalle 07.30 fino al termine dei lavori
- Venerdì 7 giugno dalle 07.30 fino al termine dei lavori
- Sabato 8 giugno dalle 07.30 fino al termine dei lavori

## SEGRETERIA AIM

Il desk della Segreteria AIM sarà presente presso la Sede Congressuale (vicino all'area di registrazione) con i seguenti orari:

- 5 giugno dalle 10:00 fino al termine dei lavori
- 6 giugno dalle 08:30 fino al termine dei lavori
- 7 giugno dalle 08:30 fino al termine dei lavori
- 8 giugno dalle 08:30 fino al termine dei lavori

## ISCRIZIONI

Il Congresso è riservato per un massimo di 450 partecipanti.

La partecipazione all'evento è subordinata alla registrazione online entro venerdì 31 maggio 2024. Dopo la scadenza, sarà possibile registrarsi direttamente presso la Sede Congressuale.

### LATE REGISTRATION

DAL 23 APRILE 2024

---

**SOCIO AIM** **285,00 €**

**SOCI AIM UNDER 35 ANNI** **198,00 €**

**NON SOCIO AIM** **400,00 €**

IVA (22%) esclusa

---

## LA QUOTA DI ISCRIZIONE INCLUDE:

Ammissione alle sessioni scientifiche  
Cocktail di benvenuto 5 giugno 2024  
Cena Sociale 7 giugno 2024 c/o Villa Miani  
Coffee break e Lunch come da programma  
Attestato di partecipazione  
Kit congressuale  
Badge nominale  
Programma scientifico

## METODO DI PAGAMENTO

Online - Bonifico bancario e carta di credito  
Onsite - Bancomat e carta di credito

## CANCELLAZIONI E RIMBORSI

Le cancellazioni pervenute entro il 4 aprile 2024, daranno diritto ad un rimborso dell'importo versato meno il 30% per spese amministrative.

Le cancellazioni pervenute dopo tale data non daranno diritto ad alcun rimborso.  
Tutti i rimborsi saranno comunque effettuati dopo lo svolgimento del Congresso.

## BADGE

Al momento della registrazione, ogni partecipante registrato riceverà un badge nominale che dovrà essere sempre mostrato per accedere alle aule dove si svolgono le sessioni scientifiche, all'area espositiva, ai servizi di ristorazione e al Cocktail di Benvenuto di mercoledì 5 giugno.

## ATTESTATO DI PARTECIPAZIONE

Il certificato di partecipazione potrà essere scaricato online dopo aver completato il questionario di valutazione.

La Segreteria Organizzativa invierà un'e-mail a tutti i partecipanti il 10 giugno contenente informazioni utili per scaricarlo.

## WELCOME COCKTAIL

Il Cocktail di Benvenuto si terrà mercoledì 5 giugno dalle 19:00 alle 21:00.

Si prega di indossare il badge personale del Congresso per accedere all'area riservata.



## Accreditamento ECM

Il XXIV Congresso Nazionale Associazione Italiana di Miologia, Roma 5-8 giugno 2024 è inserito nel Piano Formativo anno 2024 First Class - Provider nr. 362 è stato accreditato presso la Commissione Nazionale per la Formazione Continua.

18 - Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultra-specialistica, ivi incluse le malattie rare e la medicina di genere

### PROFESSIONE

Farmacista

Biologo

Logopedista

Terapista Occupazionale

Psicologo

Medico Chirurgo

Infermiere Pediatrico

Fisioterapista

Infermiere

Dietista

Tecnico di Neurofisiopatologia

Terapista della Neuro e Psicomotricità dell'età Evolutiva

### DISCIPLINE

*Farmacia Territoriale;*

*Biologo*

*Logopedista*

*Terapista Occupazionale*

*Psicoterapia; Psicologia;*

*Cardiologia; Genetica Medica; Malattie Metaboliche e Diabetologia; Malattie Dell'apparato Respiratorio; Medicina Fisica e Riabilitazione; Neonatologia; Neurologia; Neuropsichiatria Infantile; Pediatria; Chirurgia Pediatrica; Neurochirurgia; Ortopedia e Traumatologia; Anestesia e Rianimazione; Laboratorio di Genetica Medica; Neurofisiopatologia, Neuroradiologia  
Pediatria (pediatri di libera scelta);  
Scienza dell'alimentazione e dietetica; Medicina Interna*

*Infermiere Pediatrico*

*Fisioterapista*

*Infermiere*

*Dietista*

*Tecnico di Neurofisiopatologia*

*Terapista della Neuro e Psicomotricità dell'età Evolutiva*

Il congresso verrà accreditato per un numero massimo di n. 450 partecipanti. Oltre tale numero e per professioni/ discipline differenti da quelle accreditate non sarà possibile rilasciare i crediti formativi. Si precisa che i crediti verranno erogati a fronte di una partecipazione del 90% ai lavori scientifici (farà fede esclusivamente l'orario di ingresso e uscita riportato nel foglio firme) e del superamento della prova di apprendimento con almeno il 75% delle risposte corrette.

**L'evento, ID ECM 362-415439, ha ottenuto 5,7 crediti formativi.**

A.ROMA Lifestyle

# Sede Congressuale



Scopri la sede

